SCHEMBL30325937

SCHEMBL30325937

C=C(F)C(=O)Nc1ccc(-c2nn3ncnc(N)c3c2-c2ccc(C(=O)NC3CC(F)(F)C3)cc2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 3/20 0.34
▸ AURKA O14965 2/20 0.34
▸ AURKB Q96GD4 1/20 0.34
▸ RIPK1 Q13546 2/20 0.33
▸ ATR Q13535 2/20 0.33
▸ BTK Q06187 2/20 0.32
▸ ABL1 P00519 2/20 0.32
▸ TNK2 Q07912 2/20 0.32
▸ EGLN1 Q9GZT9 1/20 0.32
▸ NAMPT P43490 1/20 0.32
▸ KIT P10721 2/20 0.31
▸ PLK4 O00444 1/20 0.31
▸ DAPK3 O43293 1/20 0.31
▸ ROCK2 O75116 1/20 0.31
▸ PAK4 O96013 1/20 0.31
▸ CHEK2 O96017 1/20 0.31
▸ NTRK1 P04629 1/20 0.31
▸ INSR P06213 1/20 0.31
▸ LCK P06239 1/20 0.31
▸ FYN P06241 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30325877 0.86 CSNK2A2 (0.42) RIPK1BTKTNK2
SCHEMBL31213973 0.84 RPS6KB1 (0.31) AURKAAURKBBTKABL1NAMPT
SCHEMBL30325933 0.82 KDR (0.37) PIK3CDAURKAABL1NAMPTKIT
SCHEMBL29265937 0.82 PIK3CD (0.38) PIK3CDRIPK1ABL1EGLN1KIT
SCHEMBL30325859 0.81 RIPK2 (0.36) AURKAAURKBBTKABL1NAMPT
SCHEMBL30325688 0.81 CSNK2A2 (0.42) RIPK1BTKTNK2
SCHEMBL30325945 0.78 TNK2 (0.38) AURKAAURKBBTKABL1TNK2
SCHEMBL29265794 0.78 AURKA (0.42) AURKAAURKBATRBTKABL1
SCHEMBL30325946 0.78 CSNK2A2 (0.49) BTKTNK2
SCHEMBL30326057 0.78 CSNK2A2 (0.40) RIPK1BTKTNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US claimed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP claimed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO claimed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US disclosed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP disclosed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR1, FGFR3, FGFR4 PIK3CD 889/4885AURKA 210/4885AURKB 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback